Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis

References

• Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39:733–48.
   PubMed Web of Science ®Google Scholar
• Rilutek [prescribing information, FDA package insert]. Cady, NC: Covis Pharmaceuticals, Inc.; 2016.
   Google Scholar
• Lazarevic V, Yang Y, Ivanova D, Fejtova A, Svenningsson P. Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool. Neuropharmacology 2018;143:38–48.
   PubMed Web of Science ®Google Scholar
• Frizzo MEdS, Dall’Onder LP, Dalcin KB, Souza DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol. 2004;24:123–8.
   PubMed Web of Science ®Google Scholar
• Fumagalli E, Funicello M, Rauen T, Gobbi M, Mennini T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol. 2008;578:171–6.
   PubMed Web of Science ®Google Scholar
• Theile JW, Cummins TR. Inhibition of Navβ4 peptide-mediated resurgent sodium currents in Nav1.7 channels by carbamazepine, riluzole, and anandamide. Mol Pharmacol. 2011;80:724–34.
   PubMed Web of Science ®Google Scholar
• Coderre TJ, Kumar N, Lefebvre CD, Yu JS. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J Neurochem. 2007;100:1289–99.
   PubMed Web of Science ®Google Scholar
• Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17:1942–59.
   PubMed Web of Science ®Google Scholar
• Blasco H, Patin F, Andres CR, Corcia P, Gordon PH. Amyotrophic lateral sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. Expert Opin Pharmacother. 2016;17:1669–82.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Zoccolella A. Efficacy of riluzole: who are the patients enrolled in the studies? Amyotroph Lateral Scler. 2007;8:124–5.
   PubMed Web of Science ®Google Scholar
• Beghi E, Chiò A, Couratier P, Esteban J, Hardiman O, Logroscino G, Millul A. The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler. 2011;12:1–10.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, Westeneng HJ, Nikolakopoulos S, Verhagen IE, van Es MA, Eijkmans MJC, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology 2019;92:e451–e460.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet.1996;347:1425–31.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2012(3):CD001447.
   Web of Science ®Google Scholar
• Morren JA, Galvez-Jimenez N. Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 2012;21:297–320.
   PubMed Web of Science ®Google Scholar
• Raymond J, Oskarsson B, Mehta P, Horton K. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010-2015. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:413–20.
   PubMed Web of Science ®Google Scholar
• Meininger V, Lacomblez L, Salachas F. What has changed with riluzole? J Neurol. 2000;247:19–22.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Sanjak M. Disease-modifying drug therapies. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5: 68–75.
   PubMed Web of Science ®Google Scholar
• Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:15–21.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis-a population-based study in Ireland, 1996-2000 . J Neurol. 2003;250:473–9.
   PubMed Web of Science ®Google Scholar
• Mitchell JD, O’brien MR, Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler. 2006;7:67–71.
   PubMed Web of Science ®Google Scholar
• Sívori M, Rodríguez GE, Pascansky D, Sáenz C, Sica RE. Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole. Medicina (B Aires). 2007;67:326–30.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, Lepore V. SLAP Registry. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Eur J Neurol. 2007;14:262–8.
   PubMed Web of Science ®Google Scholar
• Georgoulopoulou E, Fini N, Vinceti M, Monelli M, Vacondio P, Bianconi G, et al. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:338–45.
   PubMed Web of Science ®Google Scholar
• Rooney J, Byrne S, Heverin M, Corr B, Elamin M, Staines A, et al. Survival analysis of Irish amyotrophic lateral sclerosis patients diagnosed from 1995-2010. PLoS One. 2013;8:e74733.
   PubMed Web of Science ®Google Scholar
• Cetin H, Rath J, Füzi J, Reichardt B, Fülöp G, Koppi S, et al. Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course. Neuroepidemiology. 2015;44:6–15.
   PubMed Web of Science ®Google Scholar
• Chen L, Liu X, Tang L, Zhang N, Fan D. Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China. Front Aging Neurosci. 2016;8:246.
   PubMed Web of Science ®Google Scholar
• Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, et al. Factors predicting survival in ALS: a multicenter Italian study. J Neurol. 2017;264:54–63.
   PubMed Web of Science ®Google Scholar
• Fávero FM, Voos MC, Castro Id, Caromano FA, Oliveira ASB. Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS. Arq Neuropsiquiatr. 2017;75:515–22.
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Malerba SA, Beghi E, Fini N, Fasano A, Zucchi E, et al. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. J Neurol. 2018;265:817–27.
   PubMed Web of Science ®Google Scholar
• Stevic Z, Kostic-Dedic S, Peric S, Dedic V, Basta I, Rakocevic-Stojanovic V, et al. Prognostic factors and survival of ALS patients from Belgrade, Serbia. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:508–14.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry. 2003;74:1258–61.
   PubMed Web of Science ®Google Scholar
• Chiò A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology. 2002;59:99–103.
   PubMed Web of Science ®Google Scholar
• Lee C-C, Chiu Y-W, Wang K-C, Hwang CS, Lin KH, Lee IT, et al. Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 Cases in Taiwan. J Epidemiol. 2013;23:35–40.
   PubMed Web of Science ®Google Scholar
• Dharmadasa T, Kiernan MC. Riluzole, disease stage and survival in ALS. Lancet Neurol. 2018;17:385–6.
   PubMed Web of Science ®Google Scholar
• Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther. 2011;17:4–31.
   PubMed Web of Science ®Google Scholar
• Oberstadt M, Stieler J, Simpong DL, Römuß U, Urban N, Schaefer M, et al. TDP-43 self-interaction is modulated by redox-active compounds auranofin, chelerythrine and Riluzole. Sci Rep. 2018;8:2248.
   PubMed Web of Science ®Google Scholar
• Bissaro M, Moro S. Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment. Neural Regen Res. 2019;14:2083–5.
   PubMed Web of Science ®Google Scholar
• Fang T, Al Khleifat A, Meurgey J, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416–22.
   PubMed Web of Science ®Google Scholar
• Chen X, Wei QQ, Chen Y, Cao B, Ou R, Hou Y, et al. Clinical staging of amyotrophic lateral sclerosis in Chinese patients. Front Neurol. 2018;9:442.
   PubMed Web of Science ®Google Scholar
• Thakore NJ, Lapin BR, Pioro EP. Pooled Resource Open-Access ALS Clinical Trials Consortium. Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1–2):140–143.
   PubMedGoogle Scholar
• Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218–26.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)-revised report of an EFNS task force . Eur J Neurol. 2012;19:360–75.
   PubMed Web of Science ®Google Scholar